Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus

References

• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013;36:S67–S74.
   PubMed Web of Science ®Google Scholar
• Fowler MJ. Microvascular and macrovascular complications of diabetes. Clinical Diabetes. 2008;26:77–82.
   Google Scholar
• Kodl CT, Seaquist ER. Cognitive dysfunction and diabetes mellitus. Endocr Rev. 2008;29:494–511.
   PubMed Web of Science ®Google Scholar
• Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26:881–885.
   PubMed Web of Science ®Google Scholar
• Riddle M, Umpierrez G, DiGenio A, et al. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34:2508–2514.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2016. Diabetes Care. 2016;39(Suppl 1):S1–S112.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. American association of clinical endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement - executive summary. Endocr Pract. 2013;19:536–557.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American diabetes association and the European association for the study of diabetes. Diabetologia. 2015;58:429–442
   PubMed Web of Science ®Google Scholar
• Kalra S, Sahay RK, Schnell O, et al. Alpha-glucosidase inhibitor, acarbose, improves glycamic control and reduces body weight in type 2 diabetes: findings on indian patients from the pooled data analysis. Indian J Endocrinol Metab. 2013;17:S307–S309.
   PubMedGoogle Scholar
• Phillips LK, Deane AM, Jones KL, et al. Gastric emptying and glycaemia in health and diabetes mellitus. Nat Rev Endocrinol. 2015;11:112–128.
   PubMed Web of Science ®Google Scholar
• Deane AM, Nguyen NQ, Stevens JE, et al. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab. 2010;95:215–221.
   PubMed Web of Science ®Google Scholar
• Gonlachanvit S, Hsu CW, Boden GH, et al. Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients. Dig Dis Sci. 2003;48:488–497.
   PubMed Web of Science ®Google Scholar
• Jones KL, Horowitz M, Carney BI, et al. Gastric emptying in early noninsulin-dependent diabetes mellitus. J Nucl Med. 1996;37:1643–1648.
   PubMed Web of Science ®Google Scholar
• Woerle HJ, Albrecht M, Linke R, et al. Importance of changes in gastric emptying for postprandial plasma glucose fluxes in healthy humans. Am J Physiol Endocrinol Metab. 2008;294:E103–E109.
   PubMed Web of Science ®Google Scholar
• Horowitz M, Edelbroek MA, Wishart JM, et al. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia. 1993;36:857–862.
   PubMed Web of Science ®Google Scholar
• Marathe CS, Rayner CK, Jones KL, et al. Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care. 2013;36:1396–1405.
   PubMed Web of Science ®Google Scholar
• Chang J, Rayner CK, Jones KL, et al. Diabetic gastroparesis and its impact on glycemia. Endocrinol Metab Clin North Am. 2010;39:745–762.
   PubMed Web of Science ®Google Scholar
• Ishii M, Nakamura T, Kasai F, et al. Altered postprandial insulin requirement in IDDM patients with gastroparesis. Diabetes Care. 1994;17:901–903.
   PubMed Web of Science ®Google Scholar
• Gutniak M, Orskov C, Holst JJ, et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 1992;326:1316–1322.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741–744.
   PubMed Web of Science ®Google Scholar
• Spreckley E, Murphy KG. The L-cell in nutritional sensing and the regulation of appetite. Front Nutr. 2015;2:23.
   PubMedGoogle Scholar
• Seufert J, Gallwitz B. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes Obes Metab. 2014;16:673–688.
   PubMed Web of Science ®Google Scholar
• Ahrén B, Leguizamo DA, Miossec P, et al. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care. 2013;36:2543–2550.
   PubMed Web of Science ®Google Scholar
• Fonseca VA, Alvarado-Ruiz R, Raccah D, et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care. 2012;35:1225–1231.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013;36:2489–2496.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care. 2013;36:2497–2503.
   PubMed Web of Science ®Google Scholar
• Seino Y, Min KW, Niemoeller E, et al. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab. 2012;14:910–917.
   PubMed Web of Science ®Google Scholar
• Bolli GB, Munteanu M, Dotsenko S, et al. Efficacy and safety of lixisenatide once daily versus placebo in patients with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet Med. 2014;31:176–184.
   PubMed Web of Science ®Google Scholar
• Pinget M, Goldenberg R, Niemoeller E, et al. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab. 2013;15:1000–1007.
   PubMed Web of Science ®Google Scholar
• Yu PC, Han P, Liu X, et al. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia). Diabetes Metab Res Rev. 2014;30:726–735.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Hanefeld M, Shamanna P, et al. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). J Diabetes Complications. 2014;28:386–392.
   PubMed Web of Science ®Google Scholar
• Liu Y, Ruus P, Steinstraesser A, et al. Effect of the GLP-1 agonist lixisenatide on the pharmacokinetics of warfarin. Diabetes. 2010;59(Suppl 1): abstract 2128-PO.
   Google Scholar
• Werner U, Haschke G, Herling AW, et al. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept. 2010;164:58–64.
   PubMed Web of Science ®Google Scholar
• Gupta V. Glucagon-like peptide-1 analogues: an overview. Indian J Endocrinol Metab. 2013;17:413–421.
   PubMedGoogle Scholar
• Becker RH, Stechl J, Steinstraesser A, et al. Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects. Diabetes Metab Res Rev. 2015;31:610–618.
   PubMed Web of Science ®Google Scholar
• Lorenz M, Pfeiffer C, Steinstrasser A, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes - relationship to postprandial glycemia. Regul Pept. 2013;185:C1–C8
   PubMedGoogle Scholar
• Meier JJ, Rosenstock J, Hincelin-Mery A, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care. 2015;38:1263–1273.
   PubMed Web of Science ®Google Scholar
• Menge BA, Kapitza C, Hincelin-Mery A, et al. Impact of baseline gastric emptying on effects of lixisenatide and liraglutide in type 2 diabetes mellitus as add-on to insulin glargine. Diabetologia. 2014;54:OP75.
   Google Scholar
• Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273:E981–E988.
   PubMed Web of Science ®Google Scholar
• Jones AG, McDonald TJ, Shields BM, et al. Markers of beta-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes. Diabetes Care. 2016;39:250–257.
   PubMed Web of Science ®Google Scholar
• Bonadonna RC, Blonde L, Antsiferov MB, et al. Lixisenatide as add-on treatment among patients with different B-cell function levels as assessed by HOMA-B index. Diabetes. 2014;63:1018–P.
   Web of Science ®Google Scholar
• Anderson SL, Trujillo JM. Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness. Ther Adv Chronic Dis. 2016;7:4–17.
   PubMed Web of Science ®Google Scholar
• Christensen M, Miossec P, Larsen BD, et al. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus. Expert Opin Drug Discov. 2014;9:1223–1251
   PubMed Web of Science ®Google Scholar
• Seino Y, Akane T, Niemoeller E, et al. Long-term safety of once-daily (QD) lixisenatide in Japanese patients with type 2 diabetes (T2DM): GetGoal-Mono-Japan. J Diabetes Investig. 2012;3(Suppl1):PCS-30-5.
   Google Scholar
• Rosenstock J, Raccah D, Koranyi L, et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care. 2013;36:2945–2951.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Guerci B, Hanefeld M, et al. Prandial options to advance basal insulin glargine therapy: testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: the GetGoal Duo-2 trial. Diabetes Care. 2016;39:1318–1328
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257
   PubMed Web of Science ®Google Scholar
• Bourdel-Marchasson I, Doucet J, Bauduceau G, et al. Key priorities in managing glucose control in older people with diabetes. J Nutr Health Aging. 2009;13:685–691.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. Atlanta (GA): U.S. Department of Health and Human Services; 2014. Available from: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf
   Google Scholar
• Gunasekaran U, Gannon M. Type 2 diabetes and the aging pancreatic beta cell. Aging (Albany NY). 2011;3:565–575.
   PubMedGoogle Scholar
• Meneilly G, Alawi H, Dailey G, et al. Lixisenatide therapy in older patients with Type 2 diabetes inadequately controlled on their current antidiabetic treatment: the GetGoal-O study (NCT01798706). Diabet Med. 2016;33(Suppl 1):146 (P375).
   Google Scholar
• Hanefeld M, Berria R, Lin J, et al. Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials. Adv Ther. 2014;31:861–872.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet. 2015;54:1–21.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Medications in the kidney. Acta Clin Belg. 2008;63:76–80.
   PubMed Web of Science ®Google Scholar
• Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis. 2007;50:865–879.
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012;60:850–886.
   PubMed Web of Science ®Google Scholar
• Detournay B, Simon D, Guillausseau PJ, et al. Chronic kidney disease in type 2 diabetes patients in France: prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes. Diabetes Metab. 2012;38:102–112.
   PubMed Web of Science ®Google Scholar
• Liu Y, Ruus P. Pharmacokinetics and safety of the GLP-1 agonist AVE0010 in patients with renal impairment. Diabetes. 2009;58(Suppl 1): abstract 557.
   Google Scholar
• Sanofi-Aventis. Lyxumia® (lixisenatide) Summary of Product Characteristics. [cited 2016 Mar 11]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002445/WC500140401.pdf
   Google Scholar
• Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2015;6:19–28.
   PubMed Web of Science ®Google Scholar
• Kapitza C, Lynge J, During M, et al. Safety, tolerability, pharmacokinetics (PK) /pharmacodynamics (PD) of single escalating doses of semaglutide, a unique once weekly GLP-1 analogue, in healthy male subjects. Diabetologia. 2012;55:S341.
   Web of Science ®Google Scholar
• Nauck MA, Petrie JR, Sesti G, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care. 2016;39:231–241.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016 [cited 2016 Oct 25]; [11]. DOI: 10.1056/NEJMoa1607141.
   Web of Science ®Google Scholar
• Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728 –742.
   PubMed Web of Science ®Google Scholar
• Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:3082–3089.
   PubMed Web of Science ®Google Scholar
• Linnebjerg H, Park S, Kothare PA, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept. 2008;151:123–129.
   PubMedGoogle Scholar
• Norris SL, Lee N, Thakurta S, et al. Exenatide efficacy and safety: a systematic review. Diabet Med. 2009;26:837–846.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Kemmeries G, Holst JJ, et al. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60:1561–1565.
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39:1577–1583
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Temelkova-Kurktschiev T. The postprandial state and the risk of atherosclerosis. Diabet Med. 1997;14(Suppl 3):S6–S11.
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Koehler C, Henkel E, et al. Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD study. Risk factors in impaired glucose tolerance for atherosclerosis and diabetes. Diabet Med. 2000;17:835–840.
   PubMed Web of Science ®Google Scholar
• Hanefeld M. Postprandial hyperglycaemia: noxious effects on the vessel wall. Int J Clin Pract Suppl. 2002;129:45–50.
   PubMedGoogle Scholar
• Scognamiglio R, Negut C, de Kreutzenberg SV, et al. Effects of different insulin regimes on postprandial myocardial perfusion defects in type 2 diabetic patients. Diabetes Care. 2006;29:95–100.
   PubMed Web of Science ®Google Scholar
• Sena CM, Pereira AM, Seica R. Endothelial dysfunction - a major mediator of diabetic vascular disease. Biochim Biophys Acta. 2013;1832:2216–2231.
   PubMed Web of Science ®Google Scholar
• Rudofsky G Jr., Reismann P, Schiekofer S, et al. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs. Horm Metab Res. 2004;36:630–638.
   PubMed Web of Science ®Google Scholar
• Suh S, Kim JH. Glycemic variability: How do we measure it and why is it important? Diabetes Metab J. 2015;39:273–282.
   PubMed Web of Science ®Google Scholar
• Satya Krishna SV, Kota SK, Modi KD. Glycemic variability: clinical implications. Indian J Endocrinol Metab. 2013;17:611–619.
   PubMedGoogle Scholar
• Evans JL, Goldfine ID, Maddux BA, et al. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002;23:599–622.
   PubMed Web of Science ®Google Scholar
• Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681–1687
   PubMed Web of Science ®Google Scholar
• Kawahito S, Kitahata H, Oshita S. Problems associated with glucose toxicity: role of hyperglycemia-induced oxidative stress. World J Gastroenterol. 2009;15:4137–4142.
   PubMed Web of Science ®Google Scholar
• Perret-Guillaume C, Joly L, Benetos A. Heart rate as a risk factor for cardiovascular disease. Prog Cardiovasc Dis. 2009;52:6–10.
   PubMed Web of Science ®Google Scholar
• Cooney MT, Vartiainen E, Laatikainen T, et al. Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am Heart J. 2010;159:612–619.
   PubMed Web of Science ®Google Scholar
• Lorenz M, Owens D, Raccah D, et al. Differential effects of GLP-1 receptor agonists on 24-hour average heart rate in healthy volunteers and patients with type 2 diabetes. Diabetologia. 2015;58(Suppl 1):OP 03–16
   Google Scholar
• Goud A, Zhong J, Peters M, et al. GLP-1 agonists and blood pressure: a review of the evidence. Curr Hypertens Rep. 2016;18:16.
   PubMed Web of Science ®Google Scholar
• London: Committee for Medicinal Products for Human Use. European Medicines Agency guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. [cited 2016 Apr 21]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf
   Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Diamant M, Aroda VR, et al. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of lixisenatide and insulin glargine, versus insulin glargine in type 2 diabetes inadequately controlled on metformin monotherapy: the LixiLan proof-of-concept randomized trial. Diabetes Care. 2016;39:1579–1586
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Aronson R, Hanefeld M, et al. Clinical impact of titratable fixed-ratio combination of insulin glargine/lixisenatide vs each component alone in type 2 diabetes inadequately controlled on oral agents: LixiLan-O trial. Diabetes. 2016;65(Suppl1):186–OR.
   Google Scholar
• Aroda V, Rosenstock J, Wysham C, et al. Efficacy and safety of the insulin glargine/lixisenatide fixed-ratio combination versus insulin glargine in patients with T2DM: the LixiLan-L trial (NCT02058160). Diabetes. 2016;65(Suppl 1):238–OR.
   Google Scholar
• Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2:885–893.
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50:609–613.
   PubMed Web of Science ®Google Scholar
• Butler AE, Campbell-Thompson M, Gurlo T, et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62:2595–2604.
   PubMed Web of Science ®Google Scholar
• Tseng C-H, Lee K-Y, Tseng F-H. An updated review on cancer risk associated with incretin mimetics and enhancers. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2015;33:67–124.
   PubMed Web of Science ®Google Scholar
• Chiu WY, Shih SR, Tseng CH. A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer. Exp Diabetes Res. 2012;2012:924168.
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Riddle MC. SGLT2 inhibitors: the latest “new kids on the block”! Diabetes Care. 2015;38:352–354.
   PubMed Web of Science ®Google Scholar
• Charokopou M, McEwan P, Lister S, et al. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to metformin in the treatment of type 2 diabetes mellitus from a UK healthcare system perspective. BMC Health Serv Res. 2015;15:496.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar